logo
  

EMA Committee Recommends Pfizer, Moderna COVID-19 Booster Doses

The European Medicines Agency or EMA's human medicines committee or CHMP has concluded that an extra dose of BioNTech/Pfizer's COVID-19 vaccines Comirnaty and Moderna's Spikevax may be given to people with severely weakened immune systems, at least 28 days after their second dose, the EMA said in a statement.

The recommendation comes after studies showed that an extra dose of the vaccines increased the ability to produce antibodies against the virus that causes COVID-19 in organ transplant patients with weakened immune systems.

The EMA noted that, for people with normal immune systems, the CHMP evaluated data for Comirnaty showing a rise in antibody levels when a booster dose is given about 6 months after the second dose in people from 18 to 55 years old. Therefore, the Committee concluded that booster doses may be considered at least 6 months after the second dose for people aged 18 years and older.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT